AGP Executive Report
Last update: 7 hours agoDrug-industry oversight: The FTC and seven states are asking a federal judge to hold Martin Shkreli in contempt, alleging he violated a lifetime ban by trading pharmaceutical stocks and commenting on drugmakers. Home health: ROSE has launched a $399 tap-water test that screens for more than 100 contaminants, including PFAS, and provides personalized recommendations. Cancer research: Vir Biotechnology and Gilead will develop three masked T-cell therapies for solid tumors; Vir could receive up to $1.87 billion in upfront, milestone and royalty payments. Obesity drugs: South Korea’s Hanmi plans to launch its homegrown GLP-1 treatment Eppe this month at wholesale prices below those of Wegovy and Mounjaro. Gene therapy: In a small Phase 1 trial, a single CRISPR treatment cut LDL cholesterol and triglycerides by about half at one year. Regulation and AI: The UK’s MHRA plans faster regulatory reviews and an AI tool to check clinical-trial protocols, while researchers report a way to adapt adult-trained radiology AI for children without moving patient data between hospitals.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
